Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : n-Lorem Foundation
Deal Size : Undisclosed
Deal Type : Partnership
Details : Partnership will support the n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
February 23, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : n-Lorem Foundation
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cobitolimod
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : InDex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CONCLUDE is a randomised, double-blind, placebo-controlled, global phase III study to evaluate cobitolimod as a novel treatment for patients with moderate to severe left-sided ulcerative colitis.
Product Name : Kappaproct
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 30, 2021
Lead Product(s) : Cobitolimod
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : InDex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Foralumab
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Tiziana Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. and Europe.
Product Name : TZLS-401
Product Type : Antibody
Upfront Cash : Undisclosed
November 11, 2020
Lead Product(s) : Foralumab
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Tiziana Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SNG001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen.
Product Name : SNG001
Product Type : Protein
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : SNG001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Collaboration